Have you heard? The application for the 2023 AIM-HI Women's Venture Competition is now open to women-led, early-stage oncology companies worldwide! Launched by the AIM-HI Accelerator Fund (AIM-HI) in 2020, this one-of-its-kind annual competition empowers women scientist-entrepreneurs in oncology by…
The AIM-HI Accelerator Fund (AIM-HI), together with our partner organizations, the National Foundation for Cancer Research and the Asian Fund for Cancer Research, successfully concluded the 2022 Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship on Saturday, October…
ROCKVILLE, MD – The AIM-HI Accelerator Fund (AIM-HI) today announced the recipient of its inaugural Beacon Award for Women Leaders in Oncology as Anna D. Barker, Ph.D., Chief Strategy Officer at the Lawrence J. Ellison Institute for Transformative Medicine. She…
The AIM-HI Accelerator Fund (AIM-HI) brings together a worldwide community of leaders in oncology to bridge the gap between laboratory discoveries and clinical trials, with the ultimate goal of developing innovative cancer therapies and technologies that can save patients’ lives.…
ROCKVILLE, MD – AIM-HI Accelerator Fund, a non-for-profit that focuses on supporting early-stage biotechnology companies to progress innovative discoveries into the clinic, announced today that Mr. Lance Kawaguchi, CEO of Cure Brain Cancer Foundation, has been appointed as a strategic…
ROCKVILLE, MD – AIM-HI Accelerator Fund, a non-for-profit that focuses on supporting early-stage biotechnology companies to progress innovative discoveries into the clinic, announced today the launching of its first Beacon Award for Women Leaders in Oncology. This award will be an…
The AIM-HI Accelerator Fund (AIM-HI) just announced 6 Semi-Finalists for the 2022 AIM-HI Women’s Venture Competition! These innovative oncology start-ups have been selected from an exceptional pool of applications submitted by women scientist-entrepreneurs worldwide. The AIM-HI Women’s Venture Competition, now…
On March 31, 2022, the clinical trial application of ARB202 received ethics approval in Australia. ARB202 is an innovative bispecific antibody drug developed by AIM-HI Portfolio Company Arbele, a biotech company based in the Hong Kong Science and Technology Park.…
The year 2021 saw an unprecedented triumph of science as the world witnessed the fastest vaccine development in history. That is the result of decades of investments in basic cancer research. The AIM-HI Accelerator Fund has made decisive progress in…
We have great news to share! The 2022 AIM-HI Women’s Venture Competition is Now Open for Applications! This unique funding program, now in its third year, provides investment, coaching, and networking opportunities to women-led oncology startups. Companies with a woman…
